Memorial Sloan Kettering Cancer Center Onc. Dept..

New York, New York 90033

0 studies enrolling now · 4 studies all time

What they study most

AML, Advanced Solid Tumors, Advanced Solid Tumors With Alterations of FGFR1, 2 and or 3, Advanced Solid Tumors With FGFR1 Amplication, Advanced Solid Tumors With FGFR2 Amplication, Advanced Solid Tumors With FGFR3 Mutation, Advanced and Selected Solid Tumors, Bladder Cancer With FGFR3 Mutation or Fusion, CD79 Mutant or ABC-subtype Diffuse Large B-Cell Lymphoma, High Risk and Very High Risk MDS, Metastatic Solid Tumors, Squamous Lung Cancer With FGFR1 Amplification

Studies at this site

• Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma — Completed
• Phase 1b Trial of BGJ398/BYL719 in Solid Tumors — Completed
• A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies — Completed
• A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors — Completed